Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM4: Next Step
NCT06572228Phase 4Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 4 trial of dupilumab in asthma, sponsored by Regeneron Pharmaceuticals. Started Aug 2024; status: active, not recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06572228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572228.